3628 results for «748»
3628 results
Twenty years of progress - What we have achieved - LIVE case
27 Nov 2022 – From PCR London Valves 2022
- Part 1: TAVI by axillary access (Live)
An 80-year-old female with peripheral arterial disease presents a symptomatic severe aortic stenosis with small annulus and preserved LV function.
The operators implant, by axillary access, an Evolut pro 26 mm, on general anaesthesia, with predilatation (Balloon 18 mm) and post-dilatation...
TAVI: the future
22 Nov 2021 – From PCR London Valves 2021
This session from PCR London Valves 2021 particularly focuses on the expected expansions of TAVI to patients at a younger age and with a longer life expectancy, including a virtual live case from Clinique Pasteur, Toulouse, France.
TAVI in 2025: transforming care with the new valvular heart disease guidelines
18 Nov 2025 – From PCR London Valves 2025
This session explores how the 2025 valvular heart disease guidelines are transforming the landscape of TAVI care and clinical decision-making. It highlights the paradigm shift in managing severe aortic stenosis and provides a global perspective on the challenges and strategies for managing an expanding TAVI patient...
The impact of paravalvular leak, permanent pacemaker implantation and the planning for reinterventions on lifetime management in TAVI patients
22 May 2025 – From EuroPCR 2025
How do paravalvular leak, pacemaker implantation and reintervention planning shape lifetime outcomes in TAVI patients?
This session examines these crucial aspects through the case of a 77-year-old male with bicuspid aortic valve stenosis, HFpEF and multiple comorbidities, including diabetes, obesity and sleep apnoea.
Follow the discussion to understand...
!!!NEWSFLASH!!! Long-term outcomes of the TAVI low risk trials - from headlines to clinical practice
20 Nov 2023 – From PCR London Valves 2023
Join this session to navigate through the long-term outcomes of TAVI low-risk trials (Partner 3, Evolut Low Risk...), to enhance your ability to synthesize and interpret clinical evidence and to learn how to seamlessly integrate these insights into your Heart Team's daily clinical practice.
Defining together the ideal TAVI platform of the future
16 May 2023 – From EuroPCR 2023
How to successfully plan and access a TAVI procedure using ultrasound guidance? How to close a TAVI procedure using suture-based vessel closure devices? How to manage vascular complications during and after TAVI procedures? Join the speakers in this brainstorming session and imagine what tomorrow's ideal TAVI...
What else will become the "Next Big Thing" in Coronary Artery Disease, Peripheral Vascular, treatment of Hypertension or Cardiovascular Imaging for the Interventional Cardiologist?
15 May 2023 – From PCR Innovators Day 2023
TAVI: head-to-head trials
20 May 2026 – From EuroPCR 2026
This session presents head-to-head comparisons of TAVI devices from recent randomized trials and registries. Highlights include three-year outcomes from the SMART trial, two-year data from the LANDMARK trial on contemporary valves, comparisons of intra- and supra-annular self-expanding valves, evaluations in large annuli, the ALLEGRA trial focusing...
Mitral - Late-Breaking Trials and Innovations
28 Nov 2022 – From PCR London Valves 2022
Consult this session to discover a selection of late-breaking trials presented during PCR LV 2022: TENDyne European expeRience registry, CLASP IID trial, EXPAND G4, and much more!
Late-breaking evidence in structural and coronary interventions - Part 2
16 Nov 2025 – From PCR London Valves 2025
This session presents the latest data from pivotal late-breaking trials in interventional cardiology. Highlights include one-year results from the ADALA trial, first-in-man use of the Vivasure PerQseal Elite for large hole arterial closure, two-year outcomes of the DragonFly system in China, six-month European outcomes, and insights...
Mitral hotline: new devices
20 May 2025 – From EuroPCR 2025
Stay updated on emerging devices in mitral valve repair and replacement with this session covering novel technologies including transcatheter edge-to-edge repair (TEER), posterior leaflet restoration, transfemoral mitral annuloplasty, and a first-in-human transseptal TMVR system. Clinical trial data and early feasibility experiences provide valuable insights into advancing...
MagicTouch sirolimus-coated balloon for coronary artery disease and peripheral artery disease treatment: where evidence meets experience
20 May 2026 – From EuroPCR 2026
This session examines the clinical evidence and experiential insights regarding the MagicTouch sirolimus-coated balloon (SCB) for treating coronary and peripheral artery disease. It reviews long-term comparative data versus paclitaxel-coated balloons, application techniques, integration into current practices, and findings from major trials such as SIRONA and SIMPLE-DM,...
Transcatheter tricuspid valve interventions: the future
23 Nov 2021 – From PCR London Valves 2021
In this PCR London Valves 2021 session, observe the case of an 84-year-old, not overweight, quite active, female patient with a past history of restrictive cardiomyopathy and permanent atrial fibrillation, who presented with worsening dyspnea and obvious clinical signs of right ventricular heart failure, and discuss the...
TEER for primary mitral regurgitation - LIVE case
15 May 2024 – From EuroPCR 2024
A 76-year-old male, with previous CABG in 2015, hypertension, diabetes, and pulmonary hypertension (WHO2), presented with severe symptomatic primary MR (P3 flail).
The operators implanted 1 MitraClip (XTW) step-by-step, from the transseptal puncture to the closure, guided by TEE echo and under general anaesthesia, via the venous...
Asymptomatic severe aortic stenosis: Will these trials change my practice?
16 May 2024 – From EuroPCR 2024
This session, in collaboration with Partners in Learning, explores the emerging evidence on the use of transcatheter aortic valve implantation (TAVI) in patients with asymptomatic severe aortic stenosis. It covers data from registries and randomized controlled trials, the current guideline recommendations, and the potential impact of...
Mitral and aortic transcatheter valve-in-valve intervention - LIVE case
14 Feb 2026 – From PCR Tokyo Valves 2026
Live case
An 83-year-old male with AF, CKD (stage 3A), preserved LV function, and a history of AVR (27 mm Magna Ease) and MVR (33 mm Magna) in 2014 presented with symptomatic stenosis of the mitral bioprosthesis. A Sapien 3 valve was implanted in the Magna mitral...
Late-breaking trials of PCR Tokyo Valves 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
This session presents pivotal late-breaking trials from PCR Tokyo Valves 2026, offering one-year outcomes and real-world experiences in transcatheter valve therapies. Highlights include the AltaValve early feasibility study on atrial fixation TMVR, invasive registry insights on prosthesis-patient mismatch post-TAVR, and registry data on tricuspid and mitral...
Major Late-Breaking Trials from EuroPCR 2026
20 May 2026 – From EuroPCR 2026
This session presents major late-breaking trials from EuroPCR 2026, reviewing contemporary evidence on coronary revascularization in TAVI patients, long-term outcomes of PCI versus CABG for left main disease, and comparative effectiveness of LAA closure versus NOAC in atrial fibrillation across age groups, with clinical practice implications.
TAVI and coronary artery disease: we need the COMPLETE answer!
19 May 2026 – From EuroPCR 2026
Addressing the intersection of transcatheter aortic valve implantation (TAVI) and coronary artery disease, this session reviews contemporary surgical and interventional literature to elucidate current practices. It underscores the need for a large international randomized controlled trial to provide definitive guidance for managing patients with concomitant aortic...
Spotlight - TAVI durability: contemporary evidence and future directions
21 May 2026 – From EuroPCR 2026
Focusing on TAVI durability, this session reviews recent clinical evidence from randomized trials and large registries, examining procedural and device-related factors influencing long-term valve performance. It also discusses challenges in follow-up and implications for future trial designs and device monitoring.